In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on 4d Pharma (LBPS), with a price target of $40.00. The company’s shares closed last Wednesday at $11.82.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 28.3% and a 47.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Adverum Biotechnologies, and Taysha Gene Therapies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 4d Pharma with a $35.00 average price target, which is a 209.2% upside from current levels. In a report issued on May 13, Ladenburg Thalmann & Co. also initiated coverage with a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
4d Pharma’s market cap is currently $260.3M and has a P/E ratio of -4.80. The company has a Price to Book ratio of 14.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
